TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06690775: CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Sponsor: TORL Biotherapeutics, LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 230 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT06690775 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06690775 Rescue Dossier →